Calamos Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$105M Buy
483,670
+17,380
+4% +$3.86M 0.37% 50
2025
Q4
$107M Buy
466,290
+15,458
+3% +$3.52M 0.4% 43
2025
Q3
$104M Sell
450,832
-19,186
-4% -$3.91M 0.39% 45
2025
Q2
$87.2M Sell
470,018
-31,743
-6% -$5.9M 0.34% 56
2025
Q1
$105M Buy
501,761
+58,470
+13% +$11.4M 0.46% 37
2024
Q4
$78.8M Buy
443,291
+517
+0.1% +$95.1K 0.33% 57
2024
Q3
$87.4M Sell
442,774
-6,730
-1% -$1.26M 0.38% 49
2024
Q2
$77.1M Sell
449,504
-11,105
-2% -$1.84M 0.34% 54
2024
Q1
$83.9M Sell
460,609
-7,859
-2% -$1.35M 0.4% 48
2023
Q4
$72.6M Sell
468,468
-3,918
-0.8% -$571K 0.35% 62
2023
Q3
$70.4M Buy
472,386
+578
+0.1% +$84.9K 0.37% 54
2023
Q2
$63.6M Sell
471,808
-194
-0% -$28.4K 0.31% 69
2023
Q1
$75.2M Sell
472,002
-43,633
-8% -$6.67M 0.37% 55
2022
Q4
$83.3M Sell
515,635
-69,387
-12% -$10.6M 0.39% 50
2022
Q3
$78.5M Sell
585,022
-60,958
-9% -$8.75M 0.36% 49
2022
Q2
$98.9M Buy
645,980
+12,694
+2% +$1.94M 0.43% 35
2022
Q1
$103M Buy
633,286
+86,633
+16% +$12.6M 0.39% 40
2021
Q4
$74M Buy
546,653
+15,202
+3% +$1.8M 0.28% 82
2021
Q3
$57.3M Buy
531,451
+62,014
+13% +$7.09M 0.25% 96
2021
Q2
$52.9M Buy
469,437
+203,536
+77% +$22.9M 0.24% 98
2021
Q1
$28.8M Buy
265,901
+8,107
+3% +$867K 0.16% 157
2020
Q4
$27.6M Sell
257,794
-11,420
-4% -$1.1M 0.16% 159
2020
Q3
$23.6M Sell
269,214
-23,594
-8% -$2.22M 0.15% 168
2020
Q2
$28.7M Buy
292,808
+34,714
+13% +$3.06M 0.2% 138
2020
Q1
$19.7M Sell
258,094
-25,124
-9% -$2.14M 0.15% 185
2019
Q4
$25.1M Sell
283,218
-3,146
-1% -$261K 0.12% 211
2019
Q3
$21.7M Buy
286,364
+26,601
+10% +$1.82M 0.12% 222
2019
Q2
$18.9M Sell
259,763
-8,748
-3% -$688K 0.1% 236
2019
Q1
$21.6M Sell
268,511
-378,020
-58% -$30.9M 0.14% 211
2018
Q4
$59.6M Sell
646,531
-36,057
-5% -$3.17M 0.39% 67
2018
Q3
$64.6M Sell
682,588
-82,726
-11% -$7.84M 0.36% 65
2018
Q2
$70.9M Sell
765,314
-361,697
-32% -$35.3M 0.43% 47
2018
Q1
$107M Buy
1,127,011
+266,165
+31% +$29.2M 0.69% 23
2017
Q4
$83.3M Buy
860,846
+657,967
+324% +$62M 0.42% 33
2017
Q3
$18M Buy
202,879
+6,803
+3% +$518K 0.14% 210
2017
Q2
$14.2M Sell
196,076
-44,653
-19% -$3M 0.11% 242
2017
Q1
$15.7M Sell
240,729
-964
-0.4% -$60.6K 0.12% 223
2016
Q4
$15.1M Sell
241,693
-2,903
-1% -$177K 0.12% 204
2016
Q3
$15.4M Sell
244,596
-312,391
-56% -$20.2M 0.11% 221
2016
Q2
$34.5M Sell
556,987
-1,138,822
-67% -$69.4M 0.24% 134
2016
Q1
$96.9M Buy
1,695,809
+346,879
+26% +$19.3M 0.64% 30
2015
Q4
$79.9M Buy
1,348,930
+429,912
+47% +$24.8M 0.51% 45
2015
Q3
$50M Buy
919,018
+688,784
+299% +$44.8M 0.34% 90
2015
Q2
$15.5M Sell
230,234
-11,848
-5% -$773K 0.1% 220
2015
Q1
$14.2M Sell
242,082
-15,583
-6% -$941K 0.09% 227
2014
Q4
$16.9M Buy
257,665
+13,565
+6% +$855K 0.11% 205
2014
Q3
$14.1M Hold
244,100
0.09% 215
2014
Q2
$13.8M Buy
244,100
+16,300
+7% +$855K 0.09% 215
2014
Q1
$11.7M Hold
227,800
0.07% 228
2013
Q4
$12M Hold
227,800
0.08% 222
2013
Q3
$10.2M Hold
227,800
0.06% 239
2013
Q2
$9.42M Buy
+227,800
New +$9.96M 0.06% 226

Other funds holding ABBV

Calamos Advisors's ABBV Position: Q1 2026 in Review

Calamos Advisors increased its AbbVie (ABBV) stake by 3.7% in Q1 2026, buying an estimated $3.86M and bringing the position to 483,670 shares worth $105M. The position accounts for 0.37% of the portfolio, ranked #50.

Calamos Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $107M in Q1 2018. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Calamos Advisors held 483,670 shares of AbbVie worth $105M as of Q1 2026.
  • Calamos Advisors bought 17,380 AbbVie shares in Q1 2026, an estimated $3.86M.
  • AbbVie made up 0.37% of Calamos Advisors's portfolio in Q1 2026, its #50 holding.
  • Calamos Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's AbbVie position peaked at $107M in Q1 2018.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.